Indivior (INDV) on Monday said that it will cancel its secondary listing on the London Stock Exchange, effective July 25, ...

Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align ...

Drug maker Indivior to abandon London stock market for the US - Indivior’s exit comes after the company moved its primary ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching ...

Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary ...

Indivior said it would cancel its listing on the London Stock Exchange and keep its primary listing on New York City's Nasdaq stock exchange.

Indivior is set to delist from the London Stock Exchange after a sharp decline in the value of its shares and a management ...

Investing.com -- Indivior (LON: INDV) on Monday said it will delist from the London Stock Exchange (LON: LSEG) on July 25, ...

Indivior, a pharmaceutical firm specializing in opioid addiction treatments, plans to delist from the London Stock Exchange ...

The latest investor updates on stocks that are trending on Monday.

Australian biotech TekCyte Limited appointed a new co-CEO leadership team consisting of Tony Simula, TekCyte’s founding CEO, as well as Tara James, a commercial strategist and founder of Small and ...

(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and ...